MUC1 Vaccine in Preventing Lung Cancer in Current and Former Smokers at High Risk for Lung Cancer
Condition: Lung Carcinoma
MeSH terms: Lung Neoplasms
Intervention: Laboratory Biomarker Analysis; MUC1 Peptide-Poly-ICLC Vaccine
Intervention description: Correlative studies; Given SC
Intervention MeSH terms: Poly ICLC
Phase: Phase 1
Study type: Interventional
Primary purpose: Prevention
Intervention model: Single Group Assignment
Masking: None (Open Label)
Enrollment: 50.0
Sex: All
Minimum age: 55 Years
Maximum age: 80 Years
Healthy volunteers: No

Summary:

      This pilot phase I trial studies the side effects and how well MUC1 peptide-Poly-ICLC vaccine
      works in preventing lung cancer in current and former smokers at high risk for lung cancer.
      Vaccines made from peptides may help the body build an effective immune response to kill
      cells. MUC1 peptide-Poly-ICLC vaccine may stimulate the body's immune system and slow or stop
      the changes from normal to pre-cancer to cancer.
    

Eligibility criteria:

        Inclusion Criteria:

          -  PRE-REGISTRATION INCLUSION CRITERIA

          -  Smoking history of >= 30 pack-years AND either current smoker (still smoking or quit <
             1 year prior to pre-registration) OR former smoker (quit 1-15 years prior to
             pre-registration); Note: Pack years is determined by multiplying the number of packs
             smoked per day by the number of years smoked

          -  Eastern Cooperative Oncology Group (ECOG) performance status =< 1

          -  Computed tomography (CT) scan of the chest done =< 6 months prior to pre-registration
             showing either negative findings (no nodules) or solid or part-solid nodules < 6 mm in
             size (consistent with < 1% probability of malignancy, Lung-Reporting and Data Systems
             [RADs] version 1.0)

          -  Willingness to employ adequate contraception, if applicable; Note: women of
             child-bearing potential and men must agree to use adequate contraception (hormonal or
             barrier method of birth control; abstinence) prior to study entry and for the duration
             of study participation; should a woman become pregnant or suspect she is pregnant
             while participating in this study, she should inform her study physician immediately

          -  Ability to understand and the willingness to sign a written informed consent document

          -  REGISTRATION INCLUSION CRITERIA

          -  Leukocytes (white blood cell [WBC]) >= 3,000/microliter

          -  Neutrophils (absolute neutrophil count [ANC]) >= 1,500/microliter

          -  Platelets >= 100,000/microliter

          -  Total bilirubin =< 1.5 x institutional upper limit of normal (ULN) Note: Higher total
             bilirubin levels (=< 3 mg/dL) can be allowed if due to known benign liver condition,
             i.e. Gilbert's

          -  Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT]) =<
             1.5 x institutional upper limit of normal (ULN)

          -  Alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 1.5 x
             institutional upper limit of normal (ULN)

          -  Creatinine =< institutional upper limit of normal (ULN)

        Exclusion Criteria:

          -  PRE-REGISTRATION EXCLUSION CRITERIA

          -  History of any malignancy; exceptions: non-melanoma skin cancer or carcinoma in situ
             (CIS) of the cervix

          -  Known hepatitis B or C

          -  Receiving any other investigational agents

          -  Any prior investigational immune therapy, such as for lung cancer prevention or
             treatment or for CIS of the cervix

          -  Use of oral or systemic steroids or other systemic anti-immune therapy =< 90 days
             prior to pre-registration; Note: Use of inhaled/nasal steroids and local steroid
             injections for pain control are not exclusionary

          -  Known human immunodeficiency virus (HIV)

          -  Known autoimmune disease

          -  Known non-alcoholic steatohepatitis (NASH) or non-alcoholic fatty liver disease
             (NAFLD)

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to MUC1/Poly-ICLC

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             study requirements

          -  REGISTRATION EXCLUSION CRITERIA

          -  Any positive antinuclear antibody (ANA) titer above 1:160, even in an asymptomatic
             individual. Note: Weakly positive ANA defined as ANA titers up to 1:160 maximum (=<
             1:160) will be acceptable in an asymptomatic individual who is otherwise eligible for
             the study

          -  Pregnant or breast feeding; Note: Pregnant women are excluded from this study because
             the MUC1/Poly-ICLC vaccine may have the potential for teratogenic or abortifacient
             effects. Because there is an unknown but potential risk for adverse events (AEs) in
             nursing infants secondary to treatment of the mother with MUC1/Poly-ICLC vaccine,
             breastfeeding should be discontinued if the mother is treated with the vaccine